1
|
Opmeer L, Gazzoli I, Ballmann M, Willemsen M, Voshol GP, Grudniewska-Lawton M, Havenga M, Yallop C, Hamidi A, Gillissen G, Bakker WAM. High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains. Vaccine 2024; 42:2475-2484. [PMID: 38503660 PMCID: PMC11007389 DOI: 10.1016/j.vaccine.2024.01.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Revised: 11/21/2023] [Accepted: 01/30/2024] [Indexed: 03/21/2024]
Abstract
Sabin Inactivated Poliovirus Vaccine (sIPV) has become one of the preferred vaccination options for the last step in the Poliovirus eradication program. Sequencing of poliovirus samples is needed during the manufacturing of poliovirus vaccines to assure the safety and immunogenicity of these vaccines. Next-generation sequencing analysis is the current costly and time-consuming gold standard for monitoring the manufacturing processes. We developed a low-cost and quick, highly sensitive, and allele-specific locked nucleic acid-probe-based reverse transcription quantitative PCR alternative that can accurately detect mutations in poliovirus vaccine samples during process development, scaling up, and release. Using the frequently in vitro occurring and viral replication-impacting VP1-E295K mutation as a showcase, we show that this technology can accurately detect E295K mutations in poliovirus 2 samples to similar levels as NGS. The qPCR technology was developed employing a synthetic dsDNA fragment-based standard curve containing mixes of E295K-WT (wildtype) and Mut (mutant) synthetic dsDNA fragments ranging from 1 × 107 copies/µL to 1 × 102 copies/µL to achieve a linear correlation with R2 > 0.999, and PCR efficiencies of 95-105 %. Individual standard concentration levels achieved accuracies of ≥92 % (average 96 %) and precisions of ≤17 % (average 3.3 %) RSD. Specificity of locked nucleic acid (LNA)-probes was confirmed in the presence and absence of co-mutations in the probe-binding region. Application of the developed assay to Sabin Poliovirus type 2 production run samples, illustrated a linear relationship with an R2 of 0.994, and an average accuracy of 97.2 % of the variant (allele)-specific AS LNA qPCR result, compared to NGS. The assay showed good sensitivity for poliovirus samples, containing E295K mutation levels between 0 % and 95 % (quantification range). In conclusion, the developed AS LNA qPCR presents a valuable low-cost, and fast tool, suitable for the process development and quality control of polio vaccines.
Collapse
Affiliation(s)
- Lizet Opmeer
- Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands
| | - Isabella Gazzoli
- Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands
| | - Mónika Ballmann
- Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands
| | - Marieke Willemsen
- Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands
| | - Gerben P Voshol
- GenomeScan B.V., Plesmanlaan 1d, 2333 BZ Leiden, The Netherlands
| | | | - Menzo Havenga
- Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands
| | - Christopher Yallop
- Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands
| | - Ahd Hamidi
- Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands
| | - Gert Gillissen
- Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands
| | - Wilfried A M Bakker
- Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands.
| |
Collapse
|
2
|
Luthra A, Cheema S, Whitney S, Bakker WAM, Sandalon Z, Richardson J, Yallop C, Havenga M. Stable, high yield expression of gp145 Env glycoprotein from HIV-1 in mammalian cells. Biologicals 2021; 73:16-23. [PMID: 34366199 DOI: 10.1016/j.biologicals.2021.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Revised: 06/11/2021] [Accepted: 07/28/2021] [Indexed: 11/20/2022] Open
Abstract
The HIV-1 derived gp145 protein is being investigated by research groups as preclinical studies have shown high promise for this protein as a vaccine against HIV. However, one of the main challenges with manufacturing this promising protein has been ascribed to the low yield obtained in mammalian cell cultures. Significant improvements in gp145 production are needed to address this issue to test the gp145 protein as a potentially effective, safe, and affordable HIV vaccine. Here we describe the application of a novel expression technology to create GMP-grade CHO cell lines expressing approximately 50 μg/ml in non-optimized fed-batch culture, which is an order of magnitude higher than that obtained in existing processes. Top producing clones show a high degree of similarity in the glycosylation patterns of the purified protein to the reference standard. Conformational integrity and functionality was demonstrated via high-affinity binding to soluble CD4, using a panel of antibodies including VRC01, F105, Hk20, PG9 and 17b. In summary, we were able to generate CHO cell lines expressing HIV gp145 with significantly higher overall expression yields than currently accessible, and high product quality that could potentially be suitable for future studies assessing the efficacy and safety of gp145-based HIV vaccines.
Collapse
Affiliation(s)
- Abhinav Luthra
- Batavia Biosciences Inc., 300 TradeCenter Suite 6650, Woburn, MA, 01801, USA
| | - Sarwat Cheema
- Batavia Biosciences Inc., 300 TradeCenter Suite 6650, Woburn, MA, 01801, USA
| | - Stephen Whitney
- ABL, Inc., 9800 Medical Center Drive, Building D, Rockville, MD, 20850, USA
| | - Wilfried A M Bakker
- Batavia Biosciences Inc., 300 TradeCenter Suite 6650, Woburn, MA, 01801, USA; Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333 CL, Leiden, the Netherlands.
| | - Ziv Sandalon
- ABL, Inc., 9800 Medical Center Drive, Building D, Rockville, MD, 20850, USA
| | - James Richardson
- ABL, Inc., 9800 Medical Center Drive, Building D, Rockville, MD, 20850, USA
| | - Chris Yallop
- Batavia Biosciences Inc., 300 TradeCenter Suite 6650, Woburn, MA, 01801, USA; Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333 CL, Leiden, the Netherlands
| | - Menzo Havenga
- Batavia Biosciences Inc., 300 TradeCenter Suite 6650, Woburn, MA, 01801, USA; Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333 CL, Leiden, the Netherlands
| |
Collapse
|
3
|
Luthra A, Spanjaard RA, Cheema S, Veith N, Kober L, Wang Y, Jing T, Zhao Y, Hoeksema F, Yallop C, Havenga M, Bakker WAM. STEP® vectors for rapid generation of stable transfected CHO cell pools and clones with high expression levels and product quality homogeneity of difficult-to-express proteins. Protein Expr Purif 2021; 186:105920. [PMID: 34044134 DOI: 10.1016/j.pep.2021.105920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Revised: 05/14/2021] [Accepted: 05/19/2021] [Indexed: 11/24/2022]
Abstract
Many proteins produced in CHO cells need evaluation for their clinical and commercial potential. Traditional methods based on stable clone generation are slow and unsuitable for screening larger numbers of proteins, while transient expression technologies are fast but unpredictable regarding product quality and lacking an optional path to subcloning. The STEP® vector technology introduced here combines the best properties of both methods. STEP® vectors contain a strong transcriptional cassette driving expression of a bicistronic mRNA. The gene-of-interest (GOI) is cloned upstream of a functionally impaired zeocin resistance gene (FI-Zeo) whose translation is coupled to that of the GOI through an IRES. Stable transfected cells surviving zeocin selection produce high levels of FI-Zeo and thus, high levels of the GOI-encoded protein. By using different spacers, the translational coupling efficiency and selection strength can be controlled allowing maximization of expression of any GOI. Production of laronidase and factor VII (FVII) is presented as examples of unrelated, difficult-to-express (DTE) proteins. First step is rapid generation of transfected pools with the STEP® vectors. All high expressing surviving pools showed high product quality homogeneity as did monoclonal cell lines obtained from the top pools. Up to 500 μg/mL laronidase was obtained with virtually identical glycosylation profile as reference product. For FVII, cell specific productivity of 0.45 pg/cell/day with 50 IU/μg protein matched highest reported levels of reference product even before process development. Taken together, STEP® vector technology is ideally suited for rapid, small to large-scale production of DTE proteins compared to traditional methods.
Collapse
Affiliation(s)
- Abhinav Luthra
- Batavia Biosciences Inc., 300 Trade Center Suite 6650, Woburn, MA, USA
| | - Remco A Spanjaard
- Batavia Biosciences Inc., 300 Trade Center Suite 6650, Woburn, MA, USA
| | - Sarwat Cheema
- Batavia Biosciences Inc., 300 Trade Center Suite 6650, Woburn, MA, USA
| | - Nathalie Veith
- UGA Biopharma GmbH, Neuendorfstraße 20a, 16761, Hennigsdorf, Germany
| | - Lars Kober
- UGA Biopharma GmbH, Neuendorfstraße 20a, 16761, Hennigsdorf, Germany
| | - Yiding Wang
- COPro Bio, Room 301, Tsinghua SEM X-elerator, No.36 Haidian Xi Road, Haidian District, Beijing, China
| | - Tao Jing
- COPro Bio, Room 301, Tsinghua SEM X-elerator, No.36 Haidian Xi Road, Haidian District, Beijing, China
| | - Yi Zhao
- COPro Bio, Room 301, Tsinghua SEM X-elerator, No.36 Haidian Xi Road, Haidian District, Beijing, China
| | - Femke Hoeksema
- Batavia Biosciences Inc., 300 Trade Center Suite 6650, Woburn, MA, USA
| | - Chris Yallop
- Batavia Biosciences Inc., 300 Trade Center Suite 6650, Woburn, MA, USA
| | - Menzo Havenga
- Batavia Biosciences Inc., 300 Trade Center Suite 6650, Woburn, MA, USA
| | | |
Collapse
|
4
|
Hamidi A, Hoeksema F, Velthof P, Lemckert A, Gillissen G, Luitjens A, Bines JE, Pullagurla SR, Kumar P, Volkin DB, Joshi SB, Havenga M, Bakker WAM, Yallop C. Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine. Vaccine 2021; 39:2048-2059. [PMID: 33744044 PMCID: PMC8062787 DOI: 10.1016/j.vaccine.2021.03.033] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Revised: 03/05/2021] [Accepted: 03/06/2021] [Indexed: 11/28/2022]
Abstract
Despite solid evidence of the success of rotavirus vaccines in saving children from fatal gastroenteritis, more than 82 million infants worldwide still lack access to a rotavirus vaccine. The main barriers to global rotavirus vaccine coverage include cost, manufacturing capacity and suboptimal efficacy in low- and lower-middle income countries. One vaccine candidate with the potential to address the latter is based on the novel, naturally attenuated RV3 strain of rotavirus, RV3-BB vaccine administered in a birth dose strategy had a vaccine efficacy against severe rotavirus gastroenteritis of 94% at 12 months of age in infants in Indonesia. To further develop this vaccine candidate, a well-documented and low-cost manufacturing process is required. A target fully loaded cost of goods (COGs) of ≤$3.50 per course of three doses was set based on predicted market requirements. COGs modelling was leveraged to develop a process using Vero cells in cell factories reaching high titers, reducing or replacing expensive reagents and shortening process time to maximise output. Stable candidate liquid formulations were developed allowing two-year storage at 2-8 °C. In addition, the formulation potentially renders needless the pretreatment of vaccinees with antacid to ensure adequate gastric acid neutralization for routine oral vaccination. As a result, the formulation allows small volume dosing and reduction of supply chain costs. A dose ranging study is currently underway in Malawi that will inform the final clinical dose required. At a clinical dose of ≤6.3 log10 FFU, the COGs target of ≤$3.50 per three dose course was met. At a clinical dose of 6.5 log10 FFU, the final manufacturing process resulted in a COGs that is substantially lower than the current average market price, 2.44 USD per dose. The manufacturing and formulation processes were transferred to BioFarma in Indonesia to enable future RV3-BB vaccine production.
Collapse
Affiliation(s)
- Ahd Hamidi
- Batavia Biosciences BV, Zernikedreef 16, 2333CL Leiden, the Netherlands
| | - Femke Hoeksema
- Batavia Biosciences BV, Zernikedreef 16, 2333CL Leiden, the Netherlands
| | - Pim Velthof
- Batavia Biosciences BV, Zernikedreef 16, 2333CL Leiden, the Netherlands
| | | | - Gert Gillissen
- Batavia Biosciences BV, Zernikedreef 16, 2333CL Leiden, the Netherlands
| | - Alfred Luitjens
- Batavia Biosciences BV, Zernikedreef 16, 2333CL Leiden, the Netherlands
| | - Julie E Bines
- Murdoch Children's Research Institute, Department of Paediatrics, University of Melbourne, Department of Gastroenterology and Clinical Nutrition, Royal Children's Hospital, Parkville, Victoria 3052, Australia
| | - Swathi R Pullagurla
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA
| | - Prashant Kumar
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA
| | - David B Volkin
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA
| | - Sangeeta B Joshi
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA
| | - Menzo Havenga
- Batavia Biosciences BV, Zernikedreef 16, 2333CL Leiden, the Netherlands
| | | | - Christopher Yallop
- Batavia Biosciences BV, Zernikedreef 16, 2333CL Leiden, the Netherlands.
| |
Collapse
|
5
|
Jiang Y, van der Welle JE, Rubingh O, van Eikenhorst G, Bakker WAM, Thomassen YE. Kinetic model for adherent Vero cell growth and poliovirus production in batch bioreactors. Process Biochem 2019; 81:156-164. [PMID: 31217725 PMCID: PMC6559155 DOI: 10.1016/j.procbio.2019.03.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Mathematical model for Vero cell growth in batch bioreactors. Mathematical model for poliovirus proliferation on Vero cells. Oxygen uptake rate as process analytical technology for simple process monitoring.
The production of poliovirus vaccines in adherent Vero cells in batch bioreactors usually consists of a two-step upstream process: (1) Vero cell cultivation on microcarriers and (2) poliovirus proliferation. In this study we developed a mathematical model to describe this two-step process. We introduced the calculation of the oxygen uptake rate (OUR) and a correction of measurement for the sampling effect in order to ensure the high quality data sets. Besides the data of the OUR, we selected glucose concentration, Vero cell concentration and the virus titer for daily in process control to evaluate the progress of the process. With the selected data sets, the described model can accurately describe poliovirus production by Vero cells. Several other regular in process control samples (e.g. lactate concentration, ammonia concentration, and amino acids concentration) were excluded from the model, simplifying the process control analysis and minimizing labor.
Collapse
Affiliation(s)
- Yang Jiang
- Intravacc, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
| | | | - Olaf Rubingh
- Intravacc, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
| | | | - Wilfried A M Bakker
- Intravacc, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
| | - Yvonne E Thomassen
- Intravacc, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
| |
Collapse
|
6
|
van Eikenhorst G, Thomassen YE, van der Pol LA, Bakker WAM. Assessment of mass transfer and mixing in rigid lab-scale disposable bioreactors at low power input levels. Biotechnol Prog 2014; 30:1269-76. [DOI: 10.1002/btpr.1981] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2014] [Revised: 08/07/2014] [Indexed: 11/09/2022]
Affiliation(s)
- Gerco van Eikenhorst
- Inst. for Translational Vaccinology (Intravacc, process development); P.O. Box 450, 3720 AL Bilthoven The Netherlands
| | - Yvonne E. Thomassen
- Inst. for Translational Vaccinology (Intravacc, process development); P.O. Box 450, 3720 AL Bilthoven The Netherlands
| | - Leo A. van der Pol
- Inst. for Translational Vaccinology (Intravacc, process development); P.O. Box 450, 3720 AL Bilthoven The Netherlands
| | - Wilfried A. M. Bakker
- Inst. for Translational Vaccinology (Intravacc, process development); P.O. Box 450, 3720 AL Bilthoven The Netherlands
| |
Collapse
|
7
|
Thomassen YE, Rubingh O, Wijffels RH, van der Pol LA, Bakker WAM. Improved poliovirus D-antigen yields by application of different Vero cell cultivation methods. Vaccine 2014; 32:2782-8. [PMID: 24583004 PMCID: PMC5355417 DOI: 10.1016/j.vaccine.2014.02.022] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Vero cells were grown in batch, semi-batch, perfusion and recirculation strategies. At high cell densities (to 5 × 106 cells mL−1) cells were infected with poliovirus. Increased cell densities allowed 3 fold increase in d-antigen yield. Cell specific d-antigen yields were lower at higher cell densities. The semi-batch cultivation strategy is most promising for optimization.
Vero cells were grown adherent to microcarriers (Cytodex 1; 3 g L−1) using animal component free media in stirred-tank type bioreactors. Different strategies for media refreshment, daily media replacement (semi-batch), continuous media replacement (perfusion) and recirculation of media, were compared with batch cultivation. Cell densities increased using a feed strategy from 1 × 106 cells mL−1 during batch cultivation to 1.8, 2.7 and 5.0 × 106 cells mL−1 during semi-batch, perfusion and recirculation, respectively. The effects of these different cell culture strategies on subsequent poliovirus production were investigated. Increased cell densities allowed up to 3 times higher d-antigen levels when compared with that obtained from batch-wise Vero cell culture. However, the cell specific d-antigen production was lower when cells were infected at higher cell densities. This cell density effect is in good agreement with observations for different cell lines and virus types. From the evaluated alternative culture methods, application of a semi-batch mode of operations allowed the highest cell specific d-antigen production. The increased product yields that can easily be reached using these higher cell density cultivation methods, showed the possibility for better use of bioreactor capacity for the manufacturing of polio vaccines to ultimately reduce vaccine cost per dose. Further, the use of animal-component-free cell- and virus culture media shows opportunities for modernization of human viral vaccine manufacturing.
Collapse
Affiliation(s)
- Yvonne E Thomassen
- Institute for Translational Vaccinology, Process Development, PO BOX 450, Bilthoven 3720 AL, The Netherlands
| | - Olaf Rubingh
- Institute for Translational Vaccinology, Process Development, PO BOX 450, Bilthoven 3720 AL, The Netherlands
| | - René H Wijffels
- Wageningen University, Bioprocess Engineering, PO BOX 8129, Wageningen 6700 EV, The Netherlands
| | - Leo A van der Pol
- Institute for Translational Vaccinology, Process Development, PO BOX 450, Bilthoven 3720 AL, The Netherlands
| | - Wilfried A M Bakker
- Institute for Translational Vaccinology, Process Development, PO BOX 450, Bilthoven 3720 AL, The Netherlands.
| |
Collapse
|
8
|
Steil BP, Jorquera P, Westdijk J, Bakker WAM, Johnston RE, Barro M. A mucosal adjuvant for the inactivated poliovirus vaccine. Vaccine 2013; 32:558-63. [PMID: 24333345 DOI: 10.1016/j.vaccine.2013.11.101] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2013] [Revised: 11/20/2013] [Accepted: 11/27/2013] [Indexed: 12/19/2022]
Abstract
The eradication of poliovirus from the majority of the world has been achieved through the use of two vaccines: the inactivated poliovirus vaccine (IPV) and the live-attenuated oral poliovirus vaccine (OPV). Both vaccines are effective at preventing paralytic poliomyelitis, however, they also have significant differences. Most importantly for this work is the risk of revertant virus from OPV, the greater cost of IPV, and the low mucosal immunity induced by IPV. We and others have previously described the use of an alphavirus-based adjuvant that can induce a mucosal immune response to a co-administered antigen even when delivered at a non-mucosal site. In this report, we describe the use of an alphavirus-based adjuvant (GVI3000) with IPV. The IPV-GVI3000 vaccine significantly increased systemic IgG, mucosal IgG and mucosal IgA antibody responses to all three poliovirus serotypes in mice even when administered intramuscularly. Furthermore, GVI3000 significantly increased the potency of IPV in rat potency tests as measured by poliovirus neutralizing antibodies in serum. Thus, an IPV-GVI3000 vaccine would reduce the dose of IPV needed and provide significantly improved mucosal immunity. This vaccine could be an effective tool to use in the poliovirus eradication campaign without risking the re-introduction of revertant poliovirus derived from OPV.
Collapse
Affiliation(s)
- Benjamin P Steil
- Global Vaccines, Inc., P.O. Box 14827, Research Triangle Park, NC 27709, USA.
| | - Patricia Jorquera
- Global Vaccines, Inc., P.O. Box 14827, Research Triangle Park, NC 27709, USA
| | - Janny Westdijk
- Institute for Translational Vaccinology (Intravacc), P.O. Box 450, 3720AL Bilthoven, The Netherlands
| | - Wilfried A M Bakker
- Institute for Translational Vaccinology (Intravacc), P.O. Box 450, 3720AL Bilthoven, The Netherlands
| | - Robert E Johnston
- Global Vaccines, Inc., P.O. Box 14827, Research Triangle Park, NC 27709, USA
| | - Mario Barro
- Global Vaccines, Inc., P.O. Box 14827, Research Triangle Park, NC 27709, USA
| |
Collapse
|
9
|
Thomassen YE, van ’t Oever AG, van Oijen MGCT, Wijffels RH, van der Pol LA, Bakker WAM. Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals. PLoS One 2013; 8:e83374. [PMID: 24349497 PMCID: PMC3861478 DOI: 10.1371/journal.pone.0083374] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2013] [Accepted: 11/01/2013] [Indexed: 02/04/2023] Open
Abstract
Worldwide efforts to eradicate polio caused a tipping point in polio vaccination strategies. A switch from the oral polio vaccine, which can cause circulating and virulent vaccine derived polioviruses, to inactivated polio vaccines (IPV) is scheduled. Moreover, a manufacturing process, using attenuated virus strains instead of wild-type polioviruses, is demanded to enhance worldwide production of IPV, especially in low- and middle income countries. Therefore, development of an IPV from attenuated (Sabin) poliovirus strains (sIPV) was pursued. Starting from the current IPV production process based on wild type Salk strains, adaptations, such as lower virus cultivation temperature, were implemented. sIPV was produced at industrial scale followed by formulation of both plain and aluminium adjuvanted sIPV. The final products met the quality criteria, were immunogenic in rats, showed no toxicity in rabbits and could be released for testing in the clinic. Concluding, sIPV was developed to manufacturing scale. The technology can be transferred worldwide to support post polio-eradication biosafety goals.
Collapse
Affiliation(s)
- Yvonne E. Thomassen
- Institute for Translational Vaccinology (Intravacc), Bilthoven, The Netherlands
- * E-mail:
| | | | | | - René H. Wijffels
- Bioprocess Engineering, Wageningen University, Wageningen, The Netherlands
| | - Leo A. van der Pol
- Institute for Translational Vaccinology (Intravacc), Bilthoven, The Netherlands
| | | |
Collapse
|
10
|
Thomassen YE, van Eikenhorst G, van der Pol LA, Bakker WAM. Isoelectric Point Determination of Live Polioviruses by Capillary Isoelectric Focusing with Whole Column Imaging Detection. Anal Chem 2013; 85:6089-94. [DOI: 10.1021/ac400968q] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Yvonne E. Thomassen
- Institute for Translational Vaccinology, P.O. Box 450, 3720
AL Bilthoven, The Netherlands
| | - Gerco van Eikenhorst
- Institute for Translational Vaccinology, P.O. Box 450, 3720
AL Bilthoven, The Netherlands
| | - Leo A. van der Pol
- Institute for Translational Vaccinology, P.O. Box 450, 3720
AL Bilthoven, The Netherlands
| | - Wilfried A. M. Bakker
- Institute for Translational Vaccinology, P.O. Box 450, 3720
AL Bilthoven, The Netherlands
| |
Collapse
|
11
|
Westdijk J, Koedam P, Barro M, Steil BP, Collin N, Vedvick TS, Bakker WAM, van der Ley P, Kersten G. Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains. Vaccine 2013; 31:1298-304. [PMID: 23313617 DOI: 10.1016/j.vaccine.2012.12.076] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2012] [Revised: 12/05/2012] [Accepted: 12/24/2012] [Indexed: 12/17/2022]
Abstract
Six different adjuvants, each in combination with inactivated polio vaccine (IPV) produced with attenuated Sabin strains (sIPV), were evaluated for their ability to enhance virus neutralizing antibody titres (VNTs) in the rat potency model. The increase of VNTs was on average 3-, 15-, 24-fold with adjuvants after one immunization (serotypes 1, 2, and 3, respectively). Also after a boost immunization the VNTs of adjuvanted sIPV were on average another 7-20-27 times higher than after two inoculations of sIPV without adjuvant. The results indicate that it is feasible to increase the potency of inactivated polio vaccines by using adjuvants.
Collapse
Affiliation(s)
- Janny Westdijk
- Institute for Translational Vaccinology, Antonie van Leeuwenhoeklaan 9, 3720 AL Bilthoven, The Netherlands.
| | | | | | | | | | | | | | | | | |
Collapse
|